SEEL Seelos Therapeutics Inc

Price (delayed)

$0.5335

Market cap

$1.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$34.64

Enterprise value

$13.77M

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous ...

Highlights
The EPS has soared by 78% YoY and by 44% from the previous quarter
The net income has soared by 63% YoY and by 28% from the previous quarter
The revenue has soared by 144% YoY but it has decreased by 10% from the previous quarter
SEEL's gross profit has soared by 144% YoY but it is down by 10% from the previous quarter
The company's quick ratio has shrunk by 89% YoY and by 60% QoQ
The equity has plunged by 60% YoY

Key stats

What are the main financial stats of SEEL
Market
Shares outstanding
2.17M
Market cap
$1.16M
Enterprise value
$13.77M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.98
Earnings
Revenue
$1.97M
EBIT
-$27.02M
EBITDA
-$26.97M
Free cash flow
-$18.21M
Per share
EPS
-$34.64
Free cash flow per share
-$11.2
Book value per share
-$19.36
Revenue per share
$1.21
TBVPS
$2.22
Balance sheet
Total assets
$3.61M
Total liabilities
$36.72M
Debt
$13.14M
Equity
-$33.1M
Working capital
-$33.17M
Liquidity
Debt to equity
-0.4
Current ratio
0.1
Quick ratio
0.04
Net debt/EBITDA
-0.47
Margins
EBITDA margin
-1,366.1%
Gross margin
100%
Net margin
-1,373.6%
Operating margin
-1,905.9%
Efficiency
Return on assets
-399.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-1,369%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SEEL stock price

How has the Seelos Therapeutics stock price performed over time
Intraday
-8.02%
1 week
6.7%
1 month
-41.37%
1 year
-99.83%
YTD
-95.2%
QTD
-11.08%

Financial performance

How have Seelos Therapeutics's revenue and profit performed over time
Revenue
$1.97M
Gross profit
$1.97M
Operating income
-$37.62M
Net income
-$27.12M
Gross margin
100%
Net margin
-1,373.6%
The revenue has soared by 144% YoY but it has decreased by 10% from the previous quarter
SEEL's gross profit has soared by 144% YoY but it is down by 10% from the previous quarter
The company's net margin has surged by 85% YoY and by 20% QoQ
SEEL's operating margin has soared by 77% YoY but it is down by 3.7% QoQ

Growth

What is Seelos Therapeutics's growth rate over time

Valuation

What is Seelos Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.44
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.98
The EPS has soared by 78% YoY and by 44% from the previous quarter
The equity has plunged by 60% YoY
The revenue has soared by 144% YoY but it has decreased by 10% from the previous quarter
SEEL's P/S is 99% below its last 4 quarters average of 40.2

Efficiency

How efficient is Seelos Therapeutics business performance
The return on assets has dropped by 91% year-on-year and by 24% since the previous quarter
The ROS has soared by 85% YoY and by 20% from the previous quarter

Dividends

What is SEEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SEEL.

Financial health

How did Seelos Therapeutics financials performed over time
The total assets is 90% smaller than the total liabilities
The company's quick ratio has shrunk by 89% YoY and by 60% QoQ
The total assets has dropped by 85% year-on-year and by 33% since the previous quarter
The company's debt is 140% higher than its equity
The equity has plunged by 60% YoY
The debt to equity has soared by 51% YoY and by 4.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.